Aceclidine ophthalmic solution for Eye Diseases

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
INSIGHT Study Site #1, Andover, MA
Eye Diseases+4 More
Aceclidine ophthalmic solution - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.

Eligible Conditions

  • Eye Diseases
  • Near Vision
  • Ametropia
  • Miosis
  • Presbyopia

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 1 hour post treatment

1 hour post treatment
Primary Efficacy Variable

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

3 Treatment Groups

Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally
1 of 3
Vehicle Ophthalmic Solution dosed bilaterally
1 of 3
Combination ophthalmic solution (LNZ101) dosed bilaterally
1 of 3
Experimental Treatment

60 Total Participants · 3 Treatment Groups

Primary Treatment: Aceclidine ophthalmic solution · No Placebo Group · Phase 2

Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterallyExperimental Group · 2 Interventions: Aceclidine ophthalmic solution, Vehicle proprietary ophthalmic solution · Intervention Types: Drug, Drug
Vehicle Ophthalmic Solution dosed bilaterally
Drug
Experimental Group · 1 Intervention: Vehicle proprietary ophthalmic solution · Intervention Types: Drug
Combination ophthalmic solution (LNZ101) dosed bilaterallyExperimental Group · 2 Interventions: Aceclidine+Brimonidine combination ophthalmic solution, Vehicle proprietary ophthalmic solution · Intervention Types: Drug, Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 hour post treatment
Closest Location: INSIGHT Study Site #1 · Andover, MA
Photo of massachusetts 1Photo of massachusetts 2Photo of massachusetts 3
2022First Recorded Clinical Trial
2 TrialsResearching Eye Diseases
1 CompletedClinical Trials

Who is running the clinical trial?

Alisyn FacemireLead Sponsor
ORA, Inc.Industry Sponsor
56 Previous Clinical Trials
6,546 Total Patients Enrolled
6 Trials studying Eye Diseases
793 Patients Enrolled for Eye Diseases
Alisyn Facemire, BAStudy DirectorLENZ Therapeutics

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are able and willing to follow all instructions and attend study visits.
You have a cylinder of less than 2.00D in both eyes.
You are 45-75 years of age and any race or ethnicity at Visit 1.
You have +1.00 to -4.00 D of sphere in both eyes determined by manifest refraction documented at Visit 1.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.